|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Unexpectedly, we found that tumor cell RAGE rather than neutrophil RAGE is important for the killing process.
|
31428521 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, RAGE-targeting ADCs were not toxic in an in vivo pre-clinical mouse model, and significantly reduced tumour growth in a xenograft mouse model of disease.
|
31665084 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Conclusions:</b><i>RAGE</i> gene SNP rs1800625 was significantly associated with gastric cancer risk, and rs1800625 and rs184003 were related to tumor clinical stage, indicating that <i>RAGE</i> gene may be a gastric cancer-susceptibility gene.
|
30719146 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The heterodimer s100A8/A9 RAGE ligand is associated with hastened tumor development and metastasis.
|
30633331 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the tumor biological effects of HMGB1 and RAGE interaction.
|
31100066 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, inhibition of RAGE led to the downregulation of vascular endothelial growth factor (VEGF) and hypoxia‑inducible factor‑1α (HIF‑1α), thus suggesting that HG may influence angiogenesis and tumor metabolism via the RAGE‑NOXs pathway.
|
29693146 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These findings provide evidence that the variant A allele of rs2070600 may decrease the expression of the tumour suppressor gene RAGE, thereby increasing lung cancer risk.
|
29421442 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The receptor for advanced glycation end products (Rage) is involved in the development of various tumors and acts as an oncogenic protein.
|
29445087 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ac-APE1/Ref-1-stimulated apoptosis was markedly reduced in RAGE-knockdown tumors compared with RAGE-overexpressing tumors, even in the presence of hyperacetylation.
|
29880821 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The chronic inflammatory, hyperglycemic milieu accompanied by glycoxidative stress as in diabetes and obesity, concomitant with the formation of RAGE ligands, instigates RAGE and cancer stem cells, leading to the oncogenic transformation of normal and pre-malignant tissues towards development of neoplasms.
|
29987748 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report a rare case of primary systemic amyloid light-chain (AL) amyloidosis in biopsy-proven multiple organs with early-stage non-small cell lung cancer (NSCLC) that displayed strong staining for RAGE in the tumour tissue.
|
28056871 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To test the combined inhibition of RAGE in both tumor cell-intrinsic and non-tumor cells of the microenvironment, we performed in vivo treatment of xenografted tumors with FPS-ZM1 (1 mg/kg, two times per week).
|
27669433 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant association between RAGE expression and tumor size (p = 0.04), depth of stromal invasion (p = 0.031), lymphovascular invasion (p = 0.041) and stage of cancer (p = 0.041) was observed.
|
27814276 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our results demonstrate the link of E111A GLO1 SNP to the presence of the tumor and the connection of RAGE -429T/C and 2184A/G SNPs with the aggressiveness of the tumor.
|
25407489 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RAGE is a central driver of tumorigenesis by sustaining an inflammatory tumor microenvironment.
|
26018980 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study we suggest that extracellular HMGB1 interaction with RAGE enhances expression of oncogenic cluster miR221/222 that in turn inhibits tumor suppressor gene PTEN in two cell lines derived from human thyroid anaplastic and papillary cancers.
|
26106610 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, hypoxia and inflammation have been sequentially bridged in tumors by the discovery that alarmin receptors genes such as RAGE, P2X7 and some TLRs are activated by HIF-1α; and that, in turn, alarmin receptors strongly activate NF-κB and proinflammatory gene expression, evidencing all the hallmarks of the malignant phenotype.
|
24286852 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To test our hypothesis, we overexpressed RAGE in the WM115 human melanoma cell line that was established from a primary melanoma tumor of a patient.
|
24613454 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The receptor for advanced glycation end products (RAGE) is involved in multiple stages of tumor development and malignization.
|
24697697 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the EL-4 lymphoma model tumor growth inhibition was observed in S100A9(-/-) and TLR4(-/-), but not in RAGE(-/-) animals lacking an alternative S100A9 receptor.
|
22470535 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The receptor for advanced glycation end products (RAGE) is a multiligand receptor involved in inflammatory disorders, tumor outgrowth, diabetic complications and Alzheimer's disease (AD).
|
22571615 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
S100P has been shown to mediate tumor growth, metastasis and invasion through the binding of Ca(2+) ions, receptor for advanced glycation end products, cytoskeletal protein ezrin, calcyclin-binding protein/Siah-1-interacting protein and cathepsin D. S100P could potentially serve as diagnostic marker, prognostic/predictive indicator and therapy target for different carcinomas.
|
21947242 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
①Elevated co-expression of RAGE and HMGB1 in CCRCC was correlated positively with patients' clinical parameters including tumor size, nuclear Fuhrman grade and clinical stage.
|
21947243 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Through RAGE, S100P has been shown to mediate tumor growth, drug resistance, and metastasis.
|
20509035 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although RAGE expression has been extensively reported in many cancer types, it is now emerging as a relevant element that can continuously fuel an inflammatory milieu at the tumor microenvironment, thus changing our perception of its contribution to cancer biology.
|
20028726 |
2010 |